MCID: MGS001
MIFTS: 46

Megaesophagus

Categories: Gastrointestinal diseases

Aliases & Classifications for Megaesophagus

MalaCards integrated aliases for Megaesophagus:

Name: Megaesophagus 12 15 73
Esophageal Achalasia 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13186
MeSH 44 D004931
NCIt 50 C34811
SNOMED-CT 68 70667005
UMLS 73 C0025164

Summaries for Megaesophagus

MalaCards based summary : Megaesophagus, also known as esophageal achalasia, is related to achalasia and barrett esophagus. An important gene associated with Megaesophagus is FHIT (Fragile Histidine Triad), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Methylene blue and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Megaesophagus, also known as esophageal dilatation, is a disorder of the esophagus in humans and other... more...

Related Diseases for Megaesophagus

Diseases related to Megaesophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 achalasia 30.3 TP53 VIP
2 barrett esophagus 29.6 CDKN2A FHIT TP53
3 esophageal cancer 28.1 CDKN2A FHIT MYC TP53
4 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
5 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
6 spitz nevus 10.5 CDKN2A TP53
7 bladder carcinoma in situ 10.5 CDKN2A TP53
8 bartholin's gland benign neoplasm 10.5 CDKN2A TP53
9 vulva squamous cell carcinoma 10.5 CDKN2A TP53
10 thyroid lymphoma 10.5 CDKN2A TP53
11 nasal cavity adenocarcinoma 10.5 CDKN2A TP53
12 bone squamous cell carcinoma 10.5 CDKN2A TP53
13 scrotal carcinoma 10.5 CDKN2A TP53
14 anal squamous cell carcinoma 10.5 CDKN2A TP53
15 glycogen-rich clear cell breast carcinoma 10.5 CDKN2A TP53
16 gastric adenosquamous carcinoma 10.5 CDKN2A TP53
17 oral leukoplakia 10.5 CDKN2A TP53
18 anogenital venereal wart 10.5 CDKN2A TP53
19 schneiderian carcinoma 10.5 CDKN2A TP53
20 keratocystic odontogenic tumor 10.5 FHIT TP53
21 meningeal melanomatosis 10.5 CDKN2A TP53
22 dedifferentiated liposarcoma 10.5 CDKN2A TP53
23 oropharynx cancer 10.4 CDKN2A TP53
24 endocervical adenocarcinoma 10.4 CDKN2A TP53
25 cervix small cell carcinoma 10.4 CDKN2A TP53
26 necrotizing sialometaplasia 10.4 CDKN2A TP53
27 basaloid squamous cell carcinoma 10.4 CDKN2A TP53
28 malignant mesenchymoma 10.4 FHIT TP53
29 biliary tract neoplasm 10.4 CDKN2A TP53
30 inverted papilloma 10.4 CDKN2A TP53
31 optic nerve neoplasm 10.4 CDKN2A TP53
32 recessive dystrophic epidermolysis bullosa 10.4 CDKN2A TP53
33 vulva cancer 10.4 CDKN2A TP53
34 squamous cell papilloma 10.4 CDKN2A TP53
35 cervical intraepithelial neoplasia 10.4 CDKN2A FHIT
36 pre-malignant neoplasm 10.4 CDKN2A TP53
37 juvenile pilocytic astrocytoma 10.4 CDKN2A TP53
38 esophagitis 10.3
39 gastrointestinal system benign neoplasm 10.3 CDKN2A TP53
40 skin squamous cell carcinoma 10.3 CDKN2A TP53
41 cellular schwannoma 10.3 CDKN2A TP53
42 penile cancer 10.3 CDKN2A TP53
43 pancreatic ductal carcinoma 10.3 CDKN2A TP53
44 bladder squamous cell carcinoma 10.3 CDKN2A TP53
45 in situ carcinoma 10.3 CDKN2A TP53
46 central nervous system lymphoma 10.2 CDKN2A TP53
47 megacolon 10.2
48 chagas disease 10.2
49 pharynx cancer 10.2 CDKN2A TP53
50 brain stem glioma 10.2 FGFR1 TP53

Comorbidity relations with Megaesophagus via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Dyskinesia of Esophagus
Esophageal Disease Esophagitis
Heart Disease Ischemic Heart Disease
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Megaesophagus:



Diseases related to Megaesophagus

Symptoms & Phenotypes for Megaesophagus

GenomeRNAi Phenotypes related to Megaesophagus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.36 MYC CDKN2A
2 Decreased viability GR00221-A-2 9.36 YES1
3 Decreased viability GR00221-A-3 9.36 MYC YES1 CDKN2A
4 Decreased viability GR00221-A-4 9.36 YES1 CDKN2A
5 Decreased viability GR00402-S-2 9.36 YES1 CDKN2A MYC

MGI Mouse Phenotypes related to Megaesophagus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 TP53 FGFR1 VIP FHIT YES1 MYC
2 hematopoietic system MP:0005397 9.88 CDKN2A TP53 FGFR1 FHIT YES1 MYC
3 immune system MP:0005387 9.87 TP53 FGFR1 VIP FHIT YES1 MYC
4 digestive/alimentary MP:0005381 9.83 CDKN2A TP53 FGFR1 FHIT MYC
5 integument MP:0010771 9.8 TP53 FGFR1 FHIT YES1 MYC CDKN2A
6 mortality/aging MP:0010768 9.76 TP53 FGFR1 VIP FHIT YES1 MYC
7 reproductive system MP:0005389 9.43 NECTIN3 TP53 FGFR1 VIP MYC CDKN2A
8 skeleton MP:0005390 9.1 CDKN2A NECTIN3 TP53 FGFR1 YES1 MYC

Drugs & Therapeutics for Megaesophagus

Drugs for Megaesophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylene blue Approved, Investigational Phase 4,Not Applicable 61-73-4
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3 glucocorticoids Phase 4
4 Hormone Antagonists Phase 4
5 Hormones Phase 4
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Antineoplastic Agents, Hormonal Phase 4
9
Ceftazidime Approved Phase 2, Phase 3 78439-06-2, 72558-82-8 5481173
10 Anesthetics Phase 3,Not Applicable
11 Anti-Bacterial Agents Phase 2, Phase 3,Not Applicable
12 Antibiotics, Antitubercular Phase 2, Phase 3,Not Applicable
13 Anti-Infective Agents Phase 2, Phase 3,Not Applicable
14 Tin Fluorides Phase 3
15 Pharmaceutical Solutions Phase 2, Phase 3,Not Applicable
16
Menthol Approved Phase 1, Phase 2,Not Applicable 2216-51-5 16666
17
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068 160954
18
Naloxegol Approved Phase 2 854601-70-0
19 Peripheral Nervous System Agents Phase 2,Not Applicable
20 Narcotic Antagonists Phase 2
21 Narcotics Phase 2
22 Cola Nutraceutical Phase 2
23
Salmon Calcitonin Approved, Investigational Not Applicable 47931-85-1 16129616
24
Acetylcholine Approved Not Applicable 51-84-3 187
25
Diphenhydramine Approved, Investigational Not Applicable 147-24-0, 58-73-1 3100
26
Histamine Approved, Investigational Not Applicable 75614-87-8, 51-45-6 774
27
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337
28
Promethazine Approved, Investigational Not Applicable 60-87-7 4927
29
Ondansetron Approved Not Applicable 99614-02-5 4595
30
Amyl Nitrite Approved Not Applicable 8017-89-8, 463-04-7 10026
31 Mirabegron Approved Early Phase 1 223673-61-8 9865528
32
Esomeprazole Approved, Investigational Not Applicable 161796-78-7, 119141-88-7 4594 9579578
33
Dopamine Approved Not Applicable 51-61-6, 62-31-7 681
34
Domperidone Approved, Investigational, Vet_approved Not Applicable 57808-66-9 3151
35 tannic acid Approved, Nutraceutical Not Applicable
36
Calcitonin gene-related peptide Investigational Not Applicable 83652-28-2
37 calcitonin Not Applicable
38 Analgesics Not Applicable
39 Cephalosporins Not Applicable
40 Hemostatics Not Applicable
41 Anesthetics, Local Not Applicable
42 Hypnotics and Sedatives Not Applicable
43 Antitubercular Agents Not Applicable
44 Bone Density Conservation Agents Not Applicable
45
Histamine Phosphate Not Applicable 51-74-1 65513
46 abobotulinumtoxinA Not Applicable
47 Central Nervous System Depressants Not Applicable
48 Cholinergic Agents Not Applicable
49 Serotonin Agents Not Applicable
50 Serotonin Antagonists Not Applicable

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Assessing the Efficacy of Steroid Treatment of Achalasia Enrolling by invitation NCT01903486 Phase 4 Apo-Prednisone Cordorol, Detasone - Prednisone
3 Comparison of Esophageal and Anorectal Manometry Catheters Terminated NCT00204763 Phase 4
4 Peroral Endoscopic Myotomy for Primary Esophageal Achalasia Completed NCT01560559 Phase 3
5 Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia Active, not recruiting NCT03404739 Phase 2, Phase 3 Saline Solution;Ceftazidime
6 Efficacy of Dark Chocolate in Achalasia Patients Unknown status NCT00790465 Phase 1, Phase 2
7 Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia Unknown status NCT01302288 Phase 2
8 Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders Unknown status NCT01524458 Phase 1, Phase 2
9 Endolumenal Partial Myotomy for Esophageal Motility Disorders Unknown status NCT01302301 Phase 2
10 Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders Unknown status NCT01524471 Phase 2
11 Prospective Study on the Feasibility and Results of POEM in Idiopathic Achalasia Completed NCT02259283 Phase 2
12 Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia Completed NCT02073578 Phase 1, Phase 2
13 Pneumatic Dilatation or Surgical Myotomy for Achalasia Completed NCT02086669 Phase 2
14 Endoscopic Myotomy for the Treatment of Achalasia (Motility Disorder) of the Esophagus - POEM Procedure Completed NCT01873300 Phase 1, Phase 2
15 Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia Recruiting NCT02931565 Phase 2 IW-1701;Matching Placebo
16 Movantik for Opioid-Related Esophageal Disorders Recruiting NCT02998606 Phase 2 Naloxegol;Placebo Oral Capsule
17 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
18 Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia Unknown status NCT01649843 Not Applicable
19 POEM vs. Pneumatic Dilation for Esophageal Achalasia Unknown status NCT01768091 Not Applicable
20 Comparison Study of Conventional POEM and Hybrid POEM for Esophageal Achalasia Unknown status NCT01742494 Not Applicable
21 Hot Water Drinking Therapy in Achalasia Unknown status NCT01863966 Not Applicable
22 Achalasia: Mechanisms Underlying Treatment Failure Unknown status NCT02055469
23 POEM Versus Pneumatic Dilatation in Achalasia Cardia Unknown status NCT02025790 Not Applicable
24 Outcome of Symptoms in Patients Undergoing a Heller Myotomy Unknown status NCT00519220
25 Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01750385 Not Applicable no antibiotic prophylaxis;second-generation cephalosporin
26 A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia Unknown status NCT00188344 Not Applicable
27 POEM- Peroral Endoscopic Myotomy for Esophageal Motility Disorders Unknown status NCT01512719 Not Applicable
28 Peroral Endoscopic Remyotomy for Failed Heller Myotomy Unknown status NCT01637311 Not Applicable
29 Reversibility of Dysmotility After Gastric Banding Unknown status NCT00680030
30 Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip Unknown status NCT02446119
31 Functional Endoscopy in Neurogenic Dysphagia Unknown status NCT01995929
32 The Role That Peroral Endoscopic Myotomy (POEM) Could Play in the Treatment of Achalasia Completed NCT01584635 Not Applicable
33 Endoscopic Peroral Myotomy for Treatment of Achalasia Completed NCT01405469 Not Applicable
34 Peroral Endoscopic Myotomy (POEM) for Esophageal Motility Completed NCT02314741 Not Applicable
35 A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia Completed NCT01692106 Not Applicable
36 Genetic Evaluation of AAAS Gene in Early-Onset Achalasia and Alacrima Patients Completed NCT00856921
37 Evaluation of a Novel Endoscopic Treatment for Achalasia Completed NCT01770249 Not Applicable
38 Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia Completed NCT00490750 Not Applicable
39 A Prospective Study Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia Completed NCT01933373 Not Applicable
40 Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux Completed NCT00519441 Not Applicable
41 Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia Completed NCT01438398 Not Applicable
42 POEM Anterior Versus Posterior Approach Completed NCT02454335 Not Applicable
43 Randomized Study of Botulinum Toxin Type A for Achalasia Completed NCT00004416 Not Applicable botulinum toxin type A
44 Prospective Evaluation of a New Approach to Perform an Esophageal Myotomy: the Transesophageal Submucosa Approach Completed NCT02773589 Not Applicable
45 Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Esophageal Motility Disorders Completed NCT01525732 Not Applicable
46 Per-Oral Endoscopic Esophagomyotomy (POEM) Completed NCT01635374 Not Applicable
47 SX ELLA Esophageal Degradable BD Stent System Completed NCT01337206 Not Applicable
48 Normal Values in Ano-rectal 3D High Resolution Manometry Completed NCT01710579 Not Applicable
49 Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease Completed NCT03347903
50 The Biologic Basis of Hernia Formation Completed NCT01099033

Search NIH Clinical Center for Megaesophagus

Cochrane evidence based reviews: esophageal achalasia

Genetic Tests for Megaesophagus

Anatomical Context for Megaesophagus

MalaCards organs/tissues related to Megaesophagus:

41
Lung, Bone, Colon, Salivary Gland, Smooth Muscle, Heart

Publications for Megaesophagus

Articles related to Megaesophagus:

(show top 50) (show all 286)
# Title Authors Year
1
Esophageal achalasia and pregnancy: own observations in 43 patients and a review of the literature. ( 29931525 )
2018
2
Esophagography in Patients With Esophageal Achalasia Diagnosed With High-resolution Esophageal Manometry. ( 29969858 )
2018
3
Impact of preoperative balloon dilatation on outcomes of laparoscopic surgery in young patients with esophageal achalasia. ( 29892807 )
2018
4
Carcinoma in situ within an area of Barrett esophagus in a dog with megaesophagus. ( 29952726 )
2018
5
The relationship between esophageal cancer, chagasic megaesophagus and HPV: myths, tales or reality? ( 29687834 )
2018
6
EVALUATION OF ESOPHAGEAL ACHALASIA: FROM SYMPTOMS TO THE CHICAGO CLASSIFICATION. ( 29972404 )
2018
7
Loss of sonic hedgehog gene leads to muscle development disorder and megaesophagus in mice. ( 29768039 )
2018
8
Endoscopic pyloroplasty for adult hypertrophic pyloric stenosisA associated with esophageal achalasia. ( 29905182 )
2018
9
Per-oral endoscopic myotomy for esophageal achalasia in a case of Allgrove syndrome. ( 29383495 )
2018
10
Presence of microsatellite instability in esophageal squamous cell carcinoma associated with chagasic megaesophagus. ( 29873509 )
2018
11
Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia. ( 29196937 )
2018
12
<i>Trypanosoma cruzi</i> Detection in Colombian Patients with a Diagnosis of Esophageal Achalasia. ( 29405099 )
2018
13
Esophageal achalasia: current diagnosis and treatment. ( 29804476 )
2018
14
Less invasive than minimally invasive: peroral endoscopic myotomy with a slim scope in the treatment of esophageal achalasia. ( 29452429 )
2018
15
Obstructive bronchitis and recurrent pneumonia in esophageal achalasia in a child: A CARE compliant case report. ( 29879065 )
2018
16
Esophageal transit time in patients with chagasic megaesophagus: Lack of linear correlation between dysphagia and grade of dilatation. ( 29517674 )
2018
17
Zenker Diverticulum in Systemic Sclerosis-Related Achalasic Megaesophagus. ( 28926464 )
2017
18
Thoracoscopic Surgery in a Patient with Multiple Esophageal Carcinomas after Surgery for Esophageal Achalasia. ( 28951795 )
2017
19
Overtube-assisted pneumatic dilation for achalasia in megaesophagus. ( 29905285 )
2017
20
Chagas Disease: An Important Cause of Megaesophagus in Latin America. ( 28285728 )
2017
21
Mutational profile of TP53 in esophageal squamous cell carcinoma associated with chagasic megaesophagus. ( 28375484 )
2017
22
Overtube-assisted pneumatic dilation for achalasia in megaesophagus. ( 28232110 )
2017
23
High-resolution manometry findings in patients with achalasia and massive dilated megaesophagus. ( 28375440 )
2017
24
Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. ( 28859394 )
2017
25
EARLY AND LATE ASSESSMENT OF ESOPHAGOCARDIOPLASTY IN THE SURGICAL TREATMENT OF ADVANCED RECURRENT MEGAESOPHAGUS. ( 27706452 )
2016
26
Letter to the Editor: More on Achalasia with Megaesophagus. ( 27574362 )
2016
27
Radiological findings in megaesophagus secondary to Chagas disease: chest X-ray and esophagogram. ( 28100930 )
2016
28
Megaesophagus in Achalasia. ( 27140718 )
2016
29
Effects of laparoscopic myotomy on the esophageal motility pattern of esophageal achalasia as measured by high-resolution manometry. ( 28039638 )
2016
30
Gender differences in both the pathology and surgical outcome of patients with esophageal achalasia. ( 27129544 )
2016
31
Megaesophagus in an elderly man with achalasia: a &amp;quot;not so benign&amp;quot; condition. ( 27714664 )
2016
32
Tracheomalacia Due to Esophageal Achalasia. ( 27364977 )
2016
33
Diagnosis and management of esophageal achalasia. ( 27625387 )
2016
34
Intermittent At-Home Suctioning of Esophageal Content for Prevention of Recurrent Aspiration Pneumonia in 4 Dogs with Megaesophagus. ( 27481487 )
2016
35
Laparoscopic Heller Myotomy and Dor Fundoplication for Esophageal Achalasia: Technique and Perioperative Management. ( 27606723 )
2016
36
Long-term management of a dog with idiopathic megaesophagus and recurrent aspiration pneumonia by use of an indwelling esophagostomy tube for suction of esophageal content and esophagogastric tube feeding. ( 27853047 )
2016
37
A typical megaesophagus: interesting imaging for diagnosis. ( 25963368 )
2015
38
Achalasia with megaesophagus and tracheal compression in a young patient: A case report. ( 26209755 )
2015
39
Prevalence of gallstones in 1,229 patients submitted to surgical laparoscopic treatment of GERD and esophageal achalasia: associated cholecystectomy was a safe procedure. ( 26176247 )
2015
40
Data analyses and perspectives on laparoscopic surgery for esophageal achalasia. ( 26478674 )
2015
41
Megaesophagus associated with Myasthenia Gravis: a rare condition in humans. ( 26513950 )
2015
42
Loss of JAM-C leads to impaired esophageal innervations and megaesophagus in mice. ( 26123848 )
2015
43
Safety and efficacy of botulinum toxin injection therapy for esophageal achalasia in Japan. ( 26566311 )
2015
44
Image of the month: Colon-Like Megaesophagus. ( 26348298 )
2015
45
The Impact of Heller Myotomy on Integrated Relaxation Pressure in Esophageal Achalasia. ( 26519153 )
2015
46
Esophageal mucosal resection versus esophagectomy: a comparative study of surgical results in patients with advanced megaesophagus. ( 25861065 )
2015
47
Megaesophagus due to achalasia. ( 26160726 )
2015
48
IMAGES IN CLINICAL MEDICINE. Achalasia with Megaesophagus. ( 26672871 )
2015
49
Laparoscopic Esophagogastroplasty in Management of Megaesophagus with Axis Deviation. ( 27011598 )
2015
50
Esophagectomy with gastroplasty in advanced megaesophagus: late results of omeprazole use. ( 26648147 )
2015

Variations for Megaesophagus

Expression for Megaesophagus

Search GEO for disease gene expression data for Megaesophagus.

Pathways for Megaesophagus

Pathways related to Megaesophagus according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 CDKN2A FGFR1 MYC TP53
2 12.52 CDKN2A FGFR1 MYC TP53
3
Show member pathways
12.45 CDKN2A FGFR1 FHIT TP53
4
Show member pathways
12.42 CDKN2A FGFR1 MYC TP53
5
Show member pathways
12.35 CDKN2A MYC TP53
6 12.28 CDKN2A MYC TP53
7 12.19 CDKN2A MYC TP53
8
Show member pathways
12.13 CDKN2A MYC TP53
9 12.11 CDKN2A MYC TP53
10 12.02 FGFR1 MYC TP53
11 11.9 FGFR1 MYC TP53
12 11.89 CDKN2A MYC TP53
13 11.67 CDKN2A MYC TP53
14 11.63 CDKN2A MYC TP53
15 11.51 FHIT MYC TP53
16 11.36 MYC TP53
17 11.36 CDKN2A MYC TP53
18 11.35 CDKN2A TP53
19 11.34 MYC TP53
20 11.31 MYC YES1
21 11.3 MYC TP53
22 11.29 FGFR1 NECTIN3 YES1
23 11.27 MYC TP53
24 11.24 MYC TP53
25 11.23 FGFR1 MYC
26 11.14 FGFR1 MYC TP53
27 11.12 MYC TP53
28 11.1 CDKN2A TP53
29 11 MYC TP53
30 10.96 FGFR1 YES1
31 10.47 CDKN2A MYC TP53
32
Show member pathways
10.14 CDKN2A MYC TP53

GO Terms for Megaesophagus

Cellular components related to Megaesophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 8.92 CDKN2A FGFR1 MYC TP53

Biological processes related to Megaesophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to UV GO:0034644 9.46 MYC TP53
2 positive regulation of cell cycle GO:0045787 9.43 FGFR1 MYC
3 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.4 FHIT TP53
4 negative regulation of fibroblast proliferation GO:0048147 9.37 MYC TP53
5 response to gamma radiation GO:0010332 9.32 MYC TP53
6 positive regulation of mesenchymal cell proliferation GO:0002053 9.26 FGFR1 MYC
7 cellular response to platelet-derived growth factor stimulus GO:0036120 9.16 MYC YES1
8 cell cycle arrest GO:0007050 9.13 CDKN2A MYC TP53
9 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Megaesophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Megaesophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....